In clinical, a prolonged survival by metformin was only observed in diabetic PDA patients and no effect was found in the whole PDA population, which indicates the major effect of metformin is decreasing insulin resistance rather than anticancer effect (Chaiteerakij et al., 2016). This evidence concerns the gene INS and Patent ductus arteriosus.